CRISPR Therapeutics AG — Form 8-K

CRISPR Therapeutics, Inc. (subsidiary of CRISPR Therapeutics AG) executed an employment agreement effective October 19, 2026, with Andrew J. Silver as Chief Financial Officer. Compensation includes: $515,000 annual base salary; target bonus of 45% of base salary ($231,750) upon achievement of performance targets; equity participation in parent company's incentive plan at parent's discretion; 20 paid vacation days annually; and tax equalization payments for non-U.S. taxes. Agreement includes 6-month (or 12-month post-Change in Control) notice periods for involuntary terminations, with continued vesting and prorated bonus during notice period; noncompetition covenant with garden leave pay at 50% of highest annualized base salary if enforced; and Change in Control acceleration of time-based equity awards.